Neoadjuvant chemoimmunotherapy (nCIT) has improved outcomes in patients with locally advanced esophageal squamous cell carcinoma (LA-ESCC). However, accessible and reliable biomarkers to predict survival and pathological response remain limited. This study assessed the prognostic and predictive value of the Global Immune-Nutrition Index (GINI), cytokeratin-19 fragment (CYFRA 21 − 1), fibrinogen–albumin ratio index (FARI), and a composite score combining these markers—the GINI–CYFRA 21 − 1–FARI (GCF) score. A retrospective analysis was conducted on 138 LA-ESCC patients who received nCIT followed by radical esophagectomy between 2021 and 2023. Optimal cut-off values for GINI, CYFRA 21 − 1, and FARI were determined using X-tile software. The composite GCF score was developed accordingly. Associations with disease-free survival (DFS) were evaluated using Kaplan–Meier analysis and multivariable Cox regression. Predictive performance was assessed via time-dependent ROC curves. Tumor regression grade (TRG) was analyzed using logistic regression, and a nomogram was constructed to predict pathological response. Elevated levels of GINI (median DFS: 20 vs. not estimable [NE] months; p = 0.001), CYFRA 21 − 1 (19 vs. NE months; p < 0.001), FARI (11 vs. 26 months; p < 0.001), and higher GCF scores (0 vs. 1 vs. ≥2: 18 vs. 22 vs. NE months; p < 0.001) were associated with worse DFS. The GCF score was independently predictive of DFS (low vs. high: HR = 0.264; p = 0.028) and demonstrated consistent discriminative capacity. For pathological response, the GCF score showed predictive value for TRG (AUC = 0.625; p = 0.004) and was independently associated with poor TRG (high vs. low: OR = 2.170; p = 0.048). A nomogram incorporating the GCF score outperformed models excluding it (AUC: 0.787 vs. 0.662; p < 0.05). The GCF score—a composite of GINI, CYFRA 21 − 1, and FARI—independently predicts DFS and pathological response following nCIT and surgery in LA-ESCC, and may hold potential as a practical, blood-based biomarker. Its integration significantly enhances predictive model performance and may aid in individualized patient risk stratification.

Carcinoembryonic antigen (CEA), a pan-cancer biomarker, holds critical clinical value in aiding diagnosis and prognostic assessment of various malignancies. The development of a facile, accurate, and selective CEA detection method remains an urgent need. Herein, we developed a facile colorimetric sandwich immunoassay based on a highly defective Fe-based single-atom nanozyme (dFeSA) for detecting CEA. The dFeSA with an Fe-N3-C active site exhibited remarkable oxidase-like activity, enabling the catalytic conversion of O2 to superoxide radicals and subsequent oxidation of chromogenic substrates. This method achieved high sensitivity and specificity for CEA detection over a wide range (0.05-300 ng mL-1) and a low detection limit of 0.017 ng mL-1. Notably, the immunoassay demonstrated exceptional performance for CEA detection in real serum samples with recovery rates of 92.7%-102.6%. This colorimetric immunoassay represents a robust analytical platform for CEA detection, offering a cost-effective alternative to conventional methods and holding significant potential for early cancer diagnosis and prognostic monitoring in clinical practice.

This study investigates the impact of Bacillus Licheniformis Capsules (live) on patients with non-small cell lung cancer (NSCLC) undergoing chemotherapy. Clinical data from 79 NSCLC patients who developed grade 2-3 diarrhea during the first cycle of chemotherapy and admitted to our hospital between March 2020 and February 2023 were retrospectively analyzed and assigned to a control group (n = 42, treated from March 2020 to June 2022 with Pemetrexed + Cisplatin regimen) and a study group (n = 37, treated from July 2022 to February 2023 with Pemetrexed + Cisplatin regimen + Bacillus Licheniformis Capsules) based on their treatment regimens. The study group exhibited significantly higher overall response rate compared to the control group (P < 0.05). Post-treatment, both groups exhibited decreased levels of Enterococcus, Enterobacteriaceae, interleukin (IL)-4, IL-17, high-sensitivity C-reactive protein, and improved Functional Assessment of Cancer Therapy-Lung scores, with more pronounced improvements in the study group. Levels of Lactobacillus, Bifidobacterium, and interferon gamma increased significantly, with greater increases in the study group (P < 0.05). Both groups showed reductions in CD3+, CD4+, CD4+/CD8+ ratio, waist-to-hip ratio, and body mass index post-treatment, but these markers remained higher in the study group. CD8+ levels increased in both groups post-treatment but were much lower in the study group (P < 0.05). No significant difference was noted in the complication rates between the 2 groups. Bacillus Licheniformis Capsules (live) enhances the efficacy of chemotherapy in NSCLC patients by modulating gut microbiota, reducing inflammatory responses, and improving immune function and quality of life, without compromising safety.

INTRODUCTION:Mitochondrial unfolded protein response (UPRmt) is implicated in lung adenocarcinoma (LUAD), and our study accordingly aims to establish a model incorporating UPRmt-related genes (MRGs) for predicting the therapeutic response and prognosis in LUAD. MATERIALS AND METHODS:The data were sourced from the cancer genome atlas (TCGA) and GSE31210 dataset and MRGs were retrieved to identify those with prognostic relevance, which were applied to recognize the molecular clusters in LUAD. The cluster-specific differentially expressed genes (DEGs) were identified for the functional enrichment analysis. The independent differentially expressed MRGs were sorted out to develop a risk model. Besides, the tumor immune microenvironment was analyzed using the ESTIMATE, TIMER, MCP-counter, and ssGSEA algorithms. The data were processed with Mutect2 to evaluate the genetic mutation landscape, while the IMvigor210 cohort and pRRophetic package were utilized to predict immunotherapeutic responses and drug sensitivity. Finally, in vitro validation was performed via quantitative real-time PCR (qRT-PCR), cell counting kit-8 (CCK-8), wound healing, and Transwell assays. RESULTS:Most MRGs were higher expressed in LUAD, and CREB binding protein (CREBBP), lysine demethylase 6B (KDM6B) and leucine rich pentatricopeptide repeat containing (LRPPRC) were the top 3 genes with mutation frequency. 8 MRGs were applied to identify 2 molecular clusters, with the worst prognosis seen in cluster C1. The clusters-specific DEGs were mainly enriched in cell proliferation-related pathways and the established risk model based on 4 hub genes (ANLN, FAM83A, CPS1 and KRT6A) showed satisfying efficacy in predicting the prognosis and was negatively correlated with most immune cells. Besides, the tumor mutation burden tended to be stronger in high risk group with high gene mutation frequency. In IMvigor210 cohort, higher RiskScore was seen in patients with progressive disease and stable disease and related to a worse survival. 3 drug candidates, including Roscovitine, Rapamycin and PHA.665752 were positively correlated with RiskScore. Besides, all 4 MRGs were highly expressed in LUAD cells and the silencing of ANLN repressed the LUAD cell proliferation, migration and invasion. DISCUSSION:The established 4-MRGs signature not only serves as a robust prognostic indicator but also highlights the significant involvement of mitochondrial unfolded protein response in shaping tumor microenvironment and influencing immunotherapy outcomes in LUAD. CONCLUSION:The 4 MRGs may contribute to the understanding on UPRmt in LUAD and the development of relevant medicine in clinical practice.

Surgery is the primary treatment for thymoma. Although subxiphoid and subcostal arch thoracoscopic thymoma surgery is widely used, there is currently a lack of consensus regarding its use, nor have standards been established. Based on the surgical experience of many domestic thoracic surgery centers, the Department of Thoracic Surgery of Tangdu Hospital of Air Force Medical University has formulated this expert consensus regarding key clinical issues related to thoracoscopic thymoma surgery, including preoperative evaluation, surgical indications, preoperative preparation, surgical details, perioperative management, postoperative treatment, and follow-up. Our aim is to provide consistent and clear guidance for fellow thoracic surgeons to ensure patient safety while optimizing the treatment effect.

Lung cancer is the most commonly diagnosed type of cancer worldwide. Although TRIM65 is an important protein involved in white matter lesion, the role of TRIM65 in human cancer remains less understood. Here, we reported that TRIM65 was significantly overexpressed in lung cancer tissues compared with adjacent normal lung tissues. Furthermore, TRIM65 expression was closely related to overall survival of patients with lung cancer. Knock down of TRIM65 in two lung cancer cell lines, SPC-A-1 and NCI-H358, resulted in a significant reduction in cell proliferation, migration, invasion and adhesion and a dramatic increase in G0-G1 phase arrest and apoptosis. In vivo tumorigenesis experiment also revealed that depletion of TRIM65 expression inhibited NCI-H358 cell growth. Moreover, based on gene set enrichment analysis (GSEA) with The Cancer Genome Atlas (TCGA) dataset, we found that TRIM65 was positive related to cell cycle, metastasis up and RHOA-REG pathways, which was further validated by RT-PCR and Western blot in TRIM65 knockdown lung cancer cells and indicated a possible mechanism underlying its effects on lung cancer. In summary, our study suggests that TRIM65 may work as an oncogene and a new effective therapeutic target for lung cancer treatment.

Background: N6-methyladenosine modification has been involved in various biological processes. However, its role in non-small cell lung cancer has not been well studied. Here, we show that IGF2BP3, as an transcription factor, plays a critical oncogenic role in non-small-cell lung cancer carcinogenesis through activating FTO expression and inducing aberrant m6A modification. Methods: To evaluate the role of IGF2BP3 in non-small-cell lung cancer, we performed cell proliferation and cell cycle assays in three lung cancer cell lines. Lung cancer mouse model is used to examine the effects of IGF2BP3/FTO/N-myc on lung proliferation potentials in vivo. We analyzed the correlation between IGF2BP3 and FTO, IGF2BP3 and N-myc protein in colon cancer patients by Pearson correlation. To finally explore the relationship of IGF2BP3/FTO/N-myc, we used western blots, proliferation and cell cycle assays to confirm that IGF2BP3 may regulate lung cancer progression through FTO dependent m6A modification by stabilizing N-myc. Results: We first identified that IGF2BP3 overexpressed in non-small-cell lung cancer tissue and cells. Then, we showed that FTO was the dysregulated factor responsible for the abnormal N6-methyladenosine modification in non-small-cell lung cancer. The loss-of-function assay demonstrated that IGF2BP3 enhances FTO-mediated cell proliferation and promotes cell apoptosis, through regulating expression of target gene N-myc by reducing m6A level in mRNA transcript. Conclusion: Our study demonstrates the functional importance of IGF2BP3 and N6-methyladenosine methylation modification in the tumor progression of non-small-cell lung cancer, and provides profound insights into lung carcinogenesis and drug response.

目的 比较不同入路胸腔镜下前纵隔肿瘤切除术对患者疼痛应激和生活质量的影响.方法 选取行胸腔镜下肿瘤切除术的前纵隔肿瘤患者120例,根据入路方式分为经侧胸入路组(60例)和经剑突下入路组(60例).比较2组围术期指标、疼痛情况、疼痛应激、生活质量、中转开胸及术后并发症发生情况.结果 2组手术时间、术中出血量、肿瘤最大直径、引流时间、术后住院时间比较差异无统计学意义(P>0.05),经剑突下入路组术后首次下地时间、术后止痛药使用时间短于经侧胸入路组(P<0.05).2组术后2 d、3 d视觉模拟量表(VAS)评分均呈下降趋势(P<0.05),且经剑突下入路组低于经侧胸入路组(P<0.05).2组术后3个月健康生活量表简表(SF-36)各维度评分较术前均升高(P<0.05),且经剑突下入路组高于经侧胸入路组(P<0.05).2组术后7 d的5-羟色胺(5-HT)、促肾上腺皮质激素(ATCH)、前列腺素E2(PGE2)、神经肽Y(NPY)水平均较术前升高(P<0.05),但经剑突下入路组低于经侧胸入路组(P<0.05).2组中转开胸率及术后并发症发生率比较差异无统计学意义(P>0.05).结论 与经侧胸入路相比,经剑突下入路胸腔镜下前纵隔肿瘤切除术可获得相当的临床效果,同时还能明显减轻患者术后疼痛,改善患者生活质量,安全可靠.

Evidence suggests that Tripartite Motif Containing 11 (TRIM11) has pro-tumor activity in human non-small cell lung cancer (NSCLC). However, the roles and underlying mechanisms of TRIM11 in NSCLC have not yet been fully elucidated. In this work, human lung cancer cell lines (A549, H446, and H1975) were transfected with siRNA or lentiviruses to knockdown or overexpress TRIM11 and dual-specificity phosphatase 6 (DUSP6). The cell tumor response was assessed by determining the rate of proliferation, apoptosis, the uptake of 2-[N-(7-nitrobenz-2-oxa-1, 3-diaxol-4-yl) amino]-2-deoxyglucose (2-NBDG), and the secretion of lactic acid (LD). Dominant-negative (dn)-MEK1 was used to block the ERK1/2 pathway. The mechanism was investigated by assessing the protein levels of pyruvate kinase isozymes M2 (PKM2) and DUSP6, as well as the activation of ERK1/2 pathway. Our data confirmed the anti-cancer effect of siTRIM11 in human lung cancer by demonstrating inhibition of cancer cell proliferation, induction of apoptosis, prevention of 2-NBDG uptake, suppression of LD production, and prevention of lung cancer cell (A549) tumorigenicity in nude mice. The underlying mechanism involved the up-regulation of DUSP6 and the inhibition of ERK1/2 activity. Overexpression of TRIM11 induced tumorigenesis of NSCLC in vitro, and the activation of ERK1/2 was significantly reversed by DUSP6 overexpression or additional dn-MEK1 treatment. Interestingly, we confirmed TRIM11 as a deubiquitinase that regulated DUSP6 accumulation, indicating that lung cancer progression is regulated via the DUSP6-ERK1/2 pathway. In conclusion, TRIM11 is an oncogene in NSCLC, likely through the DUSP6-mediated ERK1/2 signaling pathway.

Objective: Peripherally inserted central venous catheter (PRT)-related thrombosis (PRT) is a serious complication that can lead to interruptions in chemotherapy and other supportive care, as well as increased hospital stay and costs. We conducted a retrospective study to evaluate the patterns of symptomatic PRT in patients with cancer undergoing chemotherapy and their risk factors. Methods: A retrospective study of 938 PICC patients from our institution between November 2014 and July 2017 was performed. Symptomatic PRT events were confirmed by color Doppler ultrasonography or computed tomography pulmonary angiography in the presence of clinical symptoms. The variables of interest were extracted from the electronic medical record system. Logistic regression analysis was used to determine the risk factors for PRT. Results: Of the 938 patients who were followed up for more than 120,000 patient-days, 63 patients (6.7%; 0.51 per 1000 catheter-days) had symptomatic PRT. Sixty-one patients were diagnosed with upper extremity venous thrombosis (UEVT), of which 18 were isolated superficial vein thrombosis (SVT), 19 were isolated deep vein thrombosis (DVT), and 24 were extensive venous thrombosis (EVT). Two patients were diagnosed with pulmonary embolism, and two patients were diagnosed with UEVT with pulmonary embolism. The symptomatic SVT occurred in 42 of 938 patients with cancer (4.5%), which accounted for 68.9% of all UEVT events. The median time to PRT was 21 days, and the median time to catheter removal in the PRT group was 66 days as compared with 117 days in the no PRT group. Predictors associated with increased risk of PRT were age >60 years (odds ratio [OR], 2.142; 95% confidence interval [CI], 1.118-4.103) and a chemotherapy regimen containing fluorouracil (OR, 2.429; 95% CI, 1.013-5.825). Hypertension with medication was a protective factor for PRT (OR, 0.306; 95% CI, 0.113-0.828). Among the 28 patients who did not remove their PICCs immediately after PRT was diagnosed, patients with SVT, DVT, and EVT had similar success rates of retaining catheters in situ after anticoagulant therapy (SVT, 83.3%; DVT, 62.5%; EVT, 75.0%; P = .667). Conclusions: Age >60 years and chemotherapy regimens containing fluorouracil were independent risk factors for PRT and hypertension with medication was associated with a lower risk of PRT in patients with cancer with PICCs receiving chemotherapy. PICCs-related SVT was a frequent type of PRT, which might need a better understanding and anticoagulant therapy in patients with cancer with PICCs.

At present, in vitro cell experiments have confirmed that RaddeaninA can effectively inhibit the proliferation of some tumor cells, but the effect of RaddeaninA on lung cancer cells has not been observed. Therefore, this study explored its effect on lung cancer cells and its mechanism of action. Human lung cancer cell lines were treated with serum-free medium and varied concentrations of Raddeanin A. Cell proliferation and apoptosis were determined using MTT, and flow cytometric assays, respectively. The intracellular level of ROS was determined using DCFH-DA assay. Protein and mRNA expressions of bax, bcl-2 and cyt c were measured using Western blotting and qRT-PCR. RaddeaninA treatment can promote PC-9 cell apoptosis in a time and dose-dependent manner (p<0.05). Treatment of PC-9 cells with Raddeanin significantly and dose-dependently increased the activities of caspase-9 and caspase-3 (p<0.05), and led to significant and dose-dependent increases in ROS levels (p<0.05). Treatment of PC-9 cells with Raddeanin A led to significant and dose-dependent decreases in mitochondrial membrane potential (p<0.05). It significantly and dose-dependently upregulated bax mRNA and protein expressions, but down-regulated bcl-2 mRNA and protein expressions significantly and dose-dependently (p<0.05). On the other hand, Raddeanin significantly and dose-dependently down-regulated cytoplasmic bax protein expression, while upregulating cyt c expression (p<0.05). Similarly, bax protein expression was significantly and dose-dependently upregulated in mitochondria, but the corresponding cyt c expression was significantly and dose-dependently down-regulated (p<0.05). Raddeanin A is a potential and effective lung cancer chemotherapy drug, which can induce lung cancer cell apoptosis and inhibit proliferation.

目的:探讨快速康复在胸腔镜手术治疗老年肺癌患者中的临床效果。方法:回顾性选取本院胸外科收治的>70岁的胸腔镜肺癌手术患者共100例，其中54例在围手术期采用了快速康复管理(观察组)，46例常规围手术期管理(对照组)。比较两组手术时间、术中出血量、手术后拔管时间、术后住院时间、术后并发症发生率、术后疼痛评分及白细胞介素-6(IL-6)和肿瘤坏死因子(TNF-α)水平。结果:两组手术时间及术中出血量比较差异无统计学意义( P>0.05)，观察组术后拔管时间、术后住院时间及心肺并发症发生率均低于对照组，两组比较差异有统计学意义( P<0.05)。观察组术后第1天及第3天疼痛评分、术后第3天血清IL-6和TNF-α水平明显低于对照组，差异有统计学意义( P<0.05)。 结论:在胸腔镜手术治疗老年肺癌患者时采用快速康复安全可靠，并可以减轻疼痛、降低术后炎症反应，减少术后并发症及缩短术后住院时间，值得在临床上推广应用。

目的:比较分析用胸腹腔镜食管癌切除术(minimally invasive esophagectomy,MIE)与开放式食管癌切除术(open esophagectomy,OE)对高龄食管癌患者进行治疗的效果.方法:对2015年1月至2018年6月苏北人民医院胸心外科收治的175例高龄(年龄≥70岁)食管癌患者的临床资料进行回顾性分析.根据手术方式的不同对其进行分组,将接受MIE的85例患者作为MIE组,将接受OE的90例患者作为OE组.然后比较两组患者手术的时间、术中的出血量、淋巴结清扫数目及术后并发症的发生情况.结果:与OE组患者相比,MIE组患者手术的时间更短,其术中的出血量更少,其淋巴结清扫数目更多,差异有统计学意义(P<0.05).在术后,MIE组患者肺部感染、气胸、心律失常、声音嘶哑、切口感染的发生率均低于OE组患者,差异有统计学意义(P<0.05).结论:与采用OE相比,用MIE对高龄食管癌患者进行治疗具有手术的时间短、淋巴结清扫彻底、患者术中的出血量少、术后并发症的发生率低等优势.

Cisplatin, as one of the front-line chemotherapeutic drugs, is employed for the treatment of esophageal squamous cell carcinoma (ESCC). However, the occurrence of cisplatin resistance and metastasis remain as challenges in clinical therapy. To investigate the mechanism involved in cisplatin resistance, in this study, we established cisplatin resistant cell lines (Res) from Eca109 and TE-1 parental cells (Par), and we observed that fibronectin (FN)-mediated cell migration and spreading abilities are significantly increased in Res cells when compared to Par cells. Furthermore, we found that the integrin α5 expression is remarkably upregulated in Res cells, and inhibition of α5 results in more apoptosis and endows the Res cells resensitize to cisplatin in vitro and in vivo. In a mechanistic manner, we identified the expression of BARD1 is significantly increased in Res cells, and silencing of BARD1 reverse the effects of α5 on cisplatin resistance. Moreover, we found that the α5/FAK/PI3K/AKT signal axis is activated in Res cells, which mediates the increased expression of BARD1, as well as the cisplatin resistance and cell survival. Thus, our results demonstrate that α5 is required for cisplatin resistance through the promotion of FAK/PI3K/AKT/BARD1 signaling to prevent cells from apoptosis and enhance the DNA damage repair ability. Taken together, our study provides plausible mechanisms of α5-mediated cisplatin resistance in ESCC cells, highlighting that inhibition of α5 may be a potential target for improving efficacy in cisplatin-based chemotherapy.

目的 探讨利用Mimics软件行三维计算机断层扫描支气管血管成像(three-dimensional computed tomography bronchography and angiography,3D-CTBA)在胸腔镜解剖性肺段切除手术中的应用价值.方法 回顾性分析2016年9月～2018年5月行胸腔镜解剖性肺段切除手术48例,术前均利用Mimics软件行3D-CTBA显示手术肺段的解剖结构,判断有无肺段支气管、血管变异,决定术中所需切断的支气管及血管,制定手术方案.结果 全组均在胸腔镜下顺利完成手术,术中情况与重建图像基本相符.手术时间(135.8±22.5)min,术中出血量(89.6±39.3)ml,术后胸管引流量(513.9±123.5)ml,术后胸管留置时间(2.9±1.3)d,术后住院日(6.1±1.2)d.术后无严重并发症发生.结论 应用3D-CTBA行胸腔镜解剖性肺段切除手术安全有效,可以实现精准的肺段切除.

目的:研究分析全腔镜下食管癌根治术对喉返神经旁淋巴结清扫的有效性及安全性.方法:选择2017年1月至2018年4月100例食管癌行手术治疗患者,其中50例行全腔镜下食管癌根治术(腔镜组),另外50例行颈胸腹三切口食管癌根治术(开放组),比较两组淋巴结清扫个数、淋巴结转移个数、双侧喉返神经旁淋巴结清扫个数、双侧喉返神经旁淋巴结转移个数;手术时间、术后前3天胸腔引流量、术后胸管留置时间、术后住院时间;并发症主要观察乳糜胸、声音嘶哑、吻合口瘘.结果:腔镜组淋巴结清扫个数、喉返神经旁淋巴结清扫个数均多于开放组(p<0.05),两组淋巴结转移个数、双侧喉返神经旁淋巴结转移个数无明显差异(p>0.05).腔镜组手术时间长于开放组(p<0.05),但两组术后前3天胸腔引流量、术后胸管留置时间、术后住院时间及术后乳糜胸、声音嘶哑及吻合口瘘发生无明显差异(p>0.05).结论:全腔镜下食管癌根治术对喉返神经旁淋巴结的清扫能达到甚至优于开放手术的效果,安全性高,不会增加患者术后并发症、术后住院时间.

目的 介绍胸腹腔镜食管癌根治术中经食管裂孔留置纵隔引流管并经右侧腹壁引出固定引流管的方法,评判其对术后吻合口瘘发生的影响.方法 回顾性分析2015年7月至2018年7月间扬州大学附属苏北人民医院胸外科收治的行胸腔镜食管癌手术患者共380例,均行经颈胸腹三切口行食管癌切除手术(McKeown手术),颈部食管胃手工吻合.其中2015年7月至2017年9月经颈部留置纵隔引流298例(A组),2017年10月至2018年7月经食管裂孔留置纵隔引流82例(B组),观察术后吻合口瘘发生的情况.两组患者均由同一组手术医生完成,颈部吻合由同一医生完成.结果 两组患者均顺利完成手术,无围手术期死亡.B组吻合口瘘发生率明显低于A组(3.66％vs.16.1％,P=0.003),其中A组发生吻合口瘘入纵隔或胸腔5例,其中1例发生食管气管瘘,经治疗后均治愈出院.结论 通过经食管裂孔留置纵隔引流管可以改善胸腹腔镜食管癌根治术后吻合口周围及纵隔内积液的引流,减少术后吻合口瘘的发生.

通信作者:史宏灿,E-mail:shihongcan@hotmail. com 气管腺样囊性癌( tracheal adenoid cystic carci-noma,TACC)是一种罕见病,其发病率低,症状不典型,很容易错过早期诊断,而导致治疗的延误.本文回顾性分析我科收治的1例气管腺样囊性癌患者的临床及术后随访资料,并结合文献,对该病的诊断及治疗进行探讨.